Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Aug 1;110(8):4588-4597.
doi: 10.1097/JS9.0000000000001478.

Higher disease burden and lower utilization in Mongolian with breast cancer: a 9-year retrospective cohort study of 18.19 million adults in China

Affiliations

Higher disease burden and lower utilization in Mongolian with breast cancer: a 9-year retrospective cohort study of 18.19 million adults in China

Jieying Chen et al. Int J Surg. .

Abstract

Background: Whether health inequalities of disease burden and medical utilization exist by ethnicity in Asian breast cancer (BC) patients remains unclear. The authors aim to measure ethnic disparities in disease burden and utilization among Mongolian and Han female BC patients in China.

Materials and methods: Based on data extracted from Inner Mongolia Regional Health Information Platform, a retrospective cohort study was established during 2012-2021. Disease burden including incidence, 5-year prevalence, mortality, survival rate, and medical cost were analyzed and compared between Han and Mongolian patients.

Results: A total of 34 878 female patients [mean (SD) age, 52.34 (10.93) years] were included among 18.19 million Chinese, and 4315 (12.03%) participants were Mongolian. Age-standardized rates of incidence are 32.68 (95% CI: 20.39-44.98) per 100 000. Higher age-specific incidence and 5-year prevalence were observed in Mongolian than in Han. The cost of BC annually per capita was significantly lower for Mongolian than Han [$1948.43 (590.11-4 776.42) vs. $2227.35 (686.65-5929.59), P <0.001]. Mongolian females showed higher all-cause mortality [30.92 (95% CI: 28.15-33.89) vs. 27.78 (95% CI: 26.77-28.83) per 1000, P =0.036] and BC-specific mortality [18.78 (95% CI: 16.64-21.13) vs. 15.22 (95% CI: 14.47-16.00) per 1000, P =0.002] than Han females. After adjusting covariates, Mongolian were associated with increased all-cause mortality [HR, 1.21, (95% CI: 1.09-1.34); P <0.001] and BC-specific mortality [HR, 1.31, (95% CI: 1.14-1.49); P <0.001].

Conclusion: The findings of this cohort study highlight a higher level of disease burden with unmet medical demand in Mongolian patients, suggesting that more practical efforts should be made for the minority. Further research is needed to explore the concrete mechanisms of the disparities as well as eliminate health disproportion.

PubMed Disclaimer

Conflict of interest statement

Dr Shengfeng Wang reports grants from Natural Science Foundation of China (No. 82173616 and No. 72342015) during the conduct of the study. Dr. Shengfeng Wang confirmed that the funders did not play a role in design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and the decision to submit the manuscript for publication. No potential conflicts of interest were disclosed for the remaining authors.

Figures

Figure 1
Figure 1
Incidence rates and 5-year prevalence rates in Inner Mongolia among breast cancer patients, per 100 000, grouped by ethnic group and age group. All results are the rates of disease burden grouped by ethnic group and age group, and the error lines in each bar chart show 95% CI. (A) Incidence rates; (B) 5-year prevalence rates. Note: Incidence rate (per 100 000) was calculated as number of new cases of breast cancer each year among population at risk each year. 5-year prevalence rate (per 100 000) was calculated as the number of people alive who diagnosed during the past 5 years among the population each year.

Similar articles

Cited by

References

    1. Sung H, Ferlay J, Siegel RL, et al. . Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2021;71:209–249. - PubMed
    1. Cao W, Chen H-D, Yu Y-W, et al. . Changing profiles of cancer burden worldwide and in China: a secondary analysis of the global cancer statistics 2020. Chin Med J 2021;134:783–791. - PMC - PubMed
    1. Liu N, Yang D-W, Wu Y-X, et al. . Burden, trends, and risk factors for breast cancer in China from 1990 to 2019 and its predictions until 2034: an up-to-date overview and comparison with those in Japan and South Korea. BMC Cancer 2022;22:826–840. - PMC - PubMed
    1. Zhang P, Zhou C, Zhao K, et al. . Associations of air pollution and greenness with global burden of breast cancer: an ecological study. Environm Sci Pollut Res 2023;30:103921–103931. - PubMed
    1. Jiang D, Niu Z, Tan X, et al. . The mortalities of female-specific cancers in China and other countries with distinct socioeconomic statuses: a longitudinal study. J Adv Res 2023;49:127–139. - PMC - PubMed